Itamar Raz, MD

Itamar Raz, MD

Professor of Internal Medicine
Head of the Diabetes Unit
Hadassah University Hospital
Jerusalem, Israel

Related Videos

How does the availability of insulin-GLP-1 RA combinations advance our ability to customize therapy in patients with T2D? Video

How does the availability of insulin-GLP-1 RA combinations advance our ability to customize therapy in patients with T2D?

How does the availability of insulin-GLP-1 RA combinations advance our ability to customize therapy in patients with T2D?

Which patient subgroups with T2D do you feel are the best candidates for fixed ratio combination therapy? Video

Which patient subgroups with T2D do you feel are the best candidates for fixed ratio combination therapy?

Which patient subgroups with T2D do you feel are the best candidates for fixed ratio combination therapy?

What are the possible advantages of the fixed-ratio combination insulin formulations such as iDegLira and iGlarLixi? Video

What are the possible advantages of the fixed-ratio combination insulin formulations such as iDegLira and iGlarLixi?

What are the possible advantages of the fixed-ratio combination insulin formulations such as iDegLira and iGlarLixi?

Can you discuss the safety profile of liraglutide based on the results of the LEADER trial, with a specific focus on pancreatitis and pancreatic cancer? Video

Can you discuss the safety profile of liraglutide based on the results of the LEADER trial, with a specific focus on pancreatitis and pancreatic cancer?

Can you discuss the safety profile of liraglutide based on the results of the LEADER trial, with a specific focus on pancreatitis and pancreatic cancer?

Can you discuss the translational implications of the LEADER trial as it relates to the deployment of the GLP-1 receptor agonist liraglutide at the front lines of diabetes care? Video

Can you discuss the translational implications of the LEADER trial as it relates to the deployment of the GLP-1 receptor agonist liraglutide at the front lines of diabetes care?

Can you discuss the translational implications of the LEADER trial as it relates to the deployment of the GLP-1 receptor agonist liraglutide at the front lines of diabetes care? And what have we learned about its safety profile?

What are the results of the primary and secondary end points in the LEADER trial? Please elaborate on CV end points as well as microvascular disease outcomes, especially nephropathic changes. Video

What are the results of the primary and secondary end points in the LEADER trial? Please elaborate on CV end points as well as microvascular disease outcomes, especially nephropathic changes.

What are the results of the primary and secondary end points in the LEADER trial? Please elaborate on CV end points as well as microvascular disease outcomes, especially nephropathic changes.

Can you give us a sense for who the patients were that were studied in the LEADER trial? What were some of their baseline characteristics? Video

Can you give us a sense for who the patients were that were studied in the LEADER trial? What were some of their baseline characteristics?

Can you give us a sense for who the patients were that were studied in the LEADER trial? What were some of their baseline characteristics?

Can you summarize the key dimensions of the LEADER trial evaluating the effect of liraglutide on CV outcomes, including its design, physiologic rationale, data collection, and clinical objectives? Video

Can you summarize the key dimensions of the LEADER trial evaluating the effect of liraglutide on CV outcomes, including its design, physiologic rationale, data collection, and clinical objectives?

Can you summarize the key dimensions of the LEADER trial evaluating the effect of liraglutide on CV outcomes, including its design, physiologic rationale, data collection, and clinical objectives?

Can you tell us what the properties are of the two fixed ratio insulin-GLP-1 RA combinations and how to titrate them? And what metabolic effects in patients with T2D are we likely to see in clinical practice? Video

Can you tell us what the properties are of the two fixed ratio insulin-GLP-1 RA combinations and how to titrate them? And what metabolic effects in patients with T2D are we likely to see in clinical practice?

Can you tell us what the properties are of the two fixed ratio insulin-GLP-1 RA combinations and how to titrate them? And what metabolic effects in patients with T2D are we likely to see in clinical practice?